Program
WRN Inhibitor MOMA-341
Its studies are mostly in Neoplasm Metastasis, led by MOMA Therapeutics.
Furthest: phase 1, since May 2, 20251 company-led study, 1 open or runningNext primary completion: Nov 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MOMA Therapeutics | 11 open or running | phase 1since May 2, 2025 | May 2, 2025 | Nov 2027phase 1 · NCT06974110 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06974110 · 132 planned · United States, Australia
Ahead
- Nov 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06974110
TargetBeta
WRN →read by rule
“An orally bioavailable allosteric inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule
Other programs on WRN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| WRN Inhibitor RO7589831rule | Bayer | phase 2 | 2 |
| WRN Inhibitor GSK4418959rule | GlaxoSmithKline | phase 2 | 1 |
| WRN Inhibitor NDI-219216rule | nimbus-wadjet-inc | phase 2 | 1 |
| WRN Inhibitor EIK1005rule | eikon-therapeutics | phase 2 | 1 |
| WRN Inhibitor AMG 436rule | Amgen | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06974110Neoplasm Metastasis · United States, Australia | 1 | Recruiting | Nov 2027 | 132 |
How it is read
Names in the registry
- “MOMA-341”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.